The Phase 2 trial, conducted through Starton’s Sargon Site Network, is expanding from two to six sites across the U.S.
The collaboration merges biomodal’s 5-base and 6-base sequencing solutions, duet +modC and duet evoC
To support this launch, ImmunityBio has established a wholly owned subsidiary in Saudi Arabia
Expansion at the Oss (NL) site adds capacity and R&D capabilities, supporting the development and manufacturing of ADCs and other novel bioconjugates from First-in-Human to commercialization
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
The acquisition marks the company’s strategic entry into the fast-growing Hormone Replacement Therapy (HRT) segment and significantly strengthens its gynaecology portfolio in India
The therapy, also known as UM171 Cell Therapy, recently received conditional marketing authorization from the European Commission
Backed by a multi-hundred-million-dollar investment, the expansion underscores Sanofi’s long-term commitment to India’s thriving life sciences ecosystem
Operational leverage kicked in during the quarter, with adjusted EBITDA rising 21% year-on-year to Rs 147 crore
The company’s consolidated revenues rose 17.5% year-on-year to Rs. 2,265 crore
Subscribe To Our Newsletter & Stay Updated
